Skip to main content

Remifentanil Side Effects

Medically reviewed by Drugs.com. Last updated on May 5, 2023.

Applies to remifentanil: intravenous powder for solution, intravenous solution.

Warning

Intravenous route (Powder for Solution)

Remifentanil exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing remifentanil.

Serious side effects of Remifentanil

Along with its needed effects, remifentanil may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking remifentanil:

More common

Less common

Rare

Other side effects of Remifentanil

Some side effects of remifentanil may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Rare

For Healthcare Professionals

Applies to remifentanil: intravenous powder for injection, intravenous solution.

General

The most commonly reported adverse reactions have included respiratory depression, bradycardia, hypotension, and skeletal muscle rigidity. In pediatric patients, the most commonly reported events were nausea, vomiting, and shivering.[Ref]

Respiratory

Cough, dyspnea, bronchospasm, laryngospasm, rhonchi, stridor, nasal congestion, pharyngitis, pleural effusion, hiccups, pulmonary edema, rales, bronchitis, and rhinorrhea have been reported in less than 1% of patients.

Common (1% to 10%): Respiratory depression

Uncommon (0.1% to 1%): Apnea, hypoxia

Frequency not reported: Cough, dyspnea, bronchospasm, laryngospasm, rhonchi, stridor, nasal congestion, pharyngitis, pleural effusion, hiccups, pulmonary edema, rales, bronchitis, rhinorrhea

Opioids:

Frequency not reported: Serious respiratory depression

Cardiovascular

Very common (10% or more): Hypotension (up to 19%)

Common (1% to 10%): Bradycardia, atrial fibrillation, atrial flutter, myocardial ischemia, edema, flushing

Uncommon (0.1% to 1%): Decreased cardiac output

Rare (0.01% to 0.1%): Tachycardia, hypertension

Frequency not reported: Various atrial and ventricular arrhythmias, heart block, ECG change consistent with myocardial ischemia, elevated CPK-MB level, syncope, premature ventricular beats, atrioventricular block

Postmarketing reports: Asystole

Cardiovascular side effects such as hypotension and bradycardia have been reported to occur most frequently during the induction and maintenance period. Bradycardia and hypotension are probably due to a centrally mediated increase in vagal nerve activity. Glycopyrrolate, atropine and/or ephedrine may be useful in treating these effects. Unlike morphine, decreases in blood pressure are not due to histamine release.

In male patients and in those patient older 65 years, the incidence of hypotension is higher. Various atrial and ventricular arrhythmias, heart block, ECG change consistent with myocardial ischemia, elevated CPK-MB level, and syncope have been reported in less than 1% of patients.

Gastrointestinal

Very common (10% or more): Nausea (up to 44%), vomiting (up to 22%)

Common (1% to 10%): Constipation, heartburn

Frequency not reported: Abdominal discomfort, xerostomia, gastro-esophageal reflux, dysphagia, diarrhea, ileus

Musculoskeletal

Common (1% to 10%): Skeletal muscle rigidity

Frequency not reported: Muscle stiffness, musculoskeletal chest pain

Rigidity may be lessened by concomitant administration of a muscle relaxant. Muscle stiffness and musculoskeletal chest pain have been reported in less than 1% of patients.

Gastrointestinal

Nausea has been reported to occur in very commonly, especially when used as a postoperative analgesic and upon discontinuation. Abdominal discomfort, xerostomia, gastro-esophageal reflux, dysphagia, diarrhea, and ileus have been reported in less than 1% of patients.

Nervous system

Involuntary movement, prolonged emergence from anesthesia, awareness under anesthesia without pain, rapid awakening from anesthesia, tremors, paresthesia, nystagmus, twitch, and seizure have been reported in less than 1% of patients.

Common (1% to 10%): Dizziness, headache

Frequency not reported: Serotonin syndrome, involuntary movement, prolonged emergence from anesthesia, awareness under anesthesia without pain, rapid awakening from anesthesia, tremors, paresthesia, nystagmus, twitch, seizure

Hypersensitivity

Anaphylactic reaction was reported in less than 1% of patients.

Frequency not reported: Anaphylactic reaction

Psychiatric

Common (1% to 10%): Agitation

Frequency not reported: Anxiety, confusion, disorientation, dysphoria, nightmares, hallucinations, amnesia

Anxiety, confusion, disorientation, dysphoria, nightmares, hallucinations, amnesia have been reported in less than 1% of patients.

Local

Erythema, pruritus, and rash at the infusion site was reported in less than 1% of patients.

Common (1% to 10%): Pain at IV site

Frequency not reported: Erythema, pruritus, rash

Dermatologic

Common (1% to 10%): Pruritus, sweating

Rash and urticaria have been reported in less than 1% of patients.

Other

Common (1% to 10%): Shivering, fever, chills, sensation of warmth

Frequency not reported: Decreased body temperature

Hematologic

Common (1% to 10%): Coagulation disorder

Frequency not reported: Anemia, lymphopenia, leukocytosis, thrombocytopenia

Anemia, lymphopenia, leukocytosis, and thrombocytopenia have been reported in less than 1% of patients.

Ocular

Common (1% to 10%): Visual disturbances

Metabolic

Frequency not reported: Hyperglycemia, electrolyte disorders, increased CPK level

Genitourinary

Frequency not reported: Urine retention, oliguria, dysuria, urine incontinence

Urine retention, oliguria, dysuria, and urine incontinence have been reported in less than 1% of patients.

Hepatic

Frequency not reported: Abnormal liver function

References

1. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.